Archived from the original on 5 June 2021
This could increase your confidence in this program while you wait to see physical changes
Following the daily ICV injection of Lira and Exe-9 on both groups, the body weight, food intake, and FBG were monitored, where the results indicated that during the whole process, more or less, Lira strengthened the effects of DJB and ameliorated T2DM in the Sham group by reducing body weight, food intake, and normalizing the glycemic status, whereas the Exe-9 showed a reverse impact (Fig
SUSTAIN-7 (N=1,201), a head-to-head trial against dulaglutide, reported mean weight loss of 5.5 to 7.3 kg at the 1 mg dose over 40 weeks, with A1C reductions of 1.8% from a baseline of approximately 8.2% 3
The once-weekly subcutaneous injection format mirrors the administration route of other GLP-1-based therapies already familiar to clinicians and patients, such as semaglutide (Wegovy/Ozempic) and tirzepatide (Mounjaro)
PubMed Central , Environmental Health Perspectives , vol